 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- AMT-116 ADC / Multitude Therap
Preliminary results from a first-in-human trial of AMT-116, a topoisomerase I inhibitor containing antibody-drug conjugate (ADC), in patients with advanced solid tumors. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4707;
P1
Dose escalation is ongoing. Clinical trial information: NCT05725291.
- || AMT-116 ADC / Multitude Therap
Enrollment open, Metastases: AMT-116 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jul 27, 2023
P1, N=48, Recruiting, Sponsor: Multitude Therapeutics Inc.
Clinical trial information: NCT05725291. Not yet recruiting --> Recruiting
- || AMT-116 ADC / Multitude Therap
New P1 trial, Metastases: AMT-116 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 13, 2023
P1, N=48, Not yet recruiting, Sponsor: Multitude Therapeutics Inc.